INCA033890-303: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Title
- A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Principal Investigator
- Daboul, Nour
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Gastrointestinal Cancers
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Meg Zafiris
- Research Specialist
- Email: margaret.zafiris@hsc.wvu.edu